CELIA VACLAVIK: Open Payments
NPI 1164703393 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,859 in 90 payments from 13 companies in 2025. Trend: 2023 $880 · 2024 $1,341 · 2025 $1,859
Food & beverage: $1,695Education: $165
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 24 | $530 |
| GENZYME CORPORATION | 11 | $280 |
| Lilly USA, LLC | 12 | $230 |
| ABBVIE INC. | 12 | $217 |
| Organon LLC | 12 | $159 |
| UCB, Inc. | 3 | $118 |
| Novartis Pharmaceuticals Corporation | 6 | $116 |
| Galderma Laboratories, L.P. | 4 | $76 |
| Arcutis Biotherapeutics, Inc. | 2 | $39 |
| Incyte Corporation | 1 | $27 |
Products named: TREMFYA, DUPIXENT, TALTZ, RINVOQ, Bimzelx, SKYRIZI, EBGLYSS, AKLIEF.
Industry payments across TX — which companies pay providers there.
